Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGON vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGON Captures Overall Composite Edge (45.0 HOLD vs 48.4 HOLD), While EDIT Leads 5–1 on Growth & Valuation Pillars

CGON Overall Winner 6-Pillar Tally: CGON 1 – 5 EDIT Matrix Metrics: CGON 5 – 3 EDIT

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (45.0/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–3 (led by Options & Positioning), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. CGON trades at $84.94 (N/M Forward P/E, -4293.5% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -167.0% operating margin) and revenue trajectory (-3.7% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGON vs EDIT
CGON NASDAQ Head-to-Head Winner
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.75β · 89% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (CGON 1 – 5 EDIT)

Columns: Metric · CGON · EDIT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale EDIT
Revenue Growth (YoY) -3.7% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.2M $50M
Market Cap $6.3B $336.5M
3. Profitability & Quality EDIT
Gross Margin N/A -73.3%
Operating Margin -4293.5% -167.0%
Net Profit Margin 0.0% -144.9%
Return on Equity (ROE) -28.3% -147.4%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$189M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $19M Net Cash $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 238.6% (85th %ile) 95.8% (38th %ile)
Put/Call OI Skew 0.35x (Call-Skewed) 0.29x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGON (5) vs EDIT (3)
Institutional Metric CGON EDIT Criterion Row Edge
Market Capitalization
Scale
$6.3B $336.5M Larger Scale CGON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-3.7% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-4293.5% -167.0% Higher Margin EDIT
Net Profit Margin
Profitability
0.0% -144.9% Higher Margin CGON
Return on Equity (ROE)
Capital Efficiency
-28.3% -147.4% Higher ROE CGON
52-Week Range Position
Momentum
84% ($37–$94) 11% ($2–$4) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
0.75β · 89% Vol 2.32β · 102% Vol Lower Realized Risk CGON
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$6.2M $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$189M ($19M Net Cash) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGON +60.87 pp
CGON: +41.93% · EDIT: -18.94%
3M Horizon CGON +45.19 pp
CGON: +11.34% · EDIT: -33.85%
6M Horizon CGON +59.68 pp
CGON: +34.98% · EDIT: -24.7%
1Y Horizon CGON +149.96 pp
CGON: +124.96% · EDIT: -25.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGON Revenue EDIT Revenue CGON Op. Margin EDIT Op. Margin Margin Leader
FY2018 N/A $30M N/A -356.1% EDIT
FY2019 N/A $20M N/A -686.4% EDIT
FY2020 N/A $90M N/A -148.6% EDIT
FY2021 N/A $30M N/A -756.1% EDIT
FY2022 N/A $20M N/A -1146.3% EDIT
FY2023 $0M $80M -27180.9% -216.6% EDIT
FY2024 $0M $30M -10067.3% -777.2% EDIT
FY2025 $0M $40M -4722.1% -394.9% EDIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ CGON vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (45.0/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–3 (led by Options & Positioning), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. CGON trades at $84.94 (N/M Forward P/E, -4293.5% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -167.0% operating margin) and revenue trajectory (-3.7% vs. +37.4% YoY). Technical & Structure Timing Caution: CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: CGON posts -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGON cumulative revenue shifted N/A while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, CGON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

EDIT screens cheaper on headline valuation multiples. CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGON (-28.3% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 89% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.